White Blood Cell Disorders

203 White Blood Cell Disorders





Epidemiology


The National Cancer Institute estimated that approximately 137,260 new cases and 54,020 deaths from hematologic malignant diseases (leukemias, lymphomas, and plasma cell disorders) occurred in 2010. On January 1, 2007, approximately 908,512 men and women living in the United States had a history of hematologic malignant disease. In adults, non-Hodgkin lymphomas and chronic lymphocytic leukemia are the most common of these diseases.1 Of a total of 26,446 childhood cancers (age 1 to 19 years) diagnosed in the United States from 2001 to 2003, leukemias were the most common (26.3%). The lymphoid leukemias were the type with the highest incidence. Lymphomas, comprising 14.6% of new childhood malignant diseases, were the third most common cancers.1,2 A history of malignant disease is a common feature in the emergency department (ED) patient population. In a retrospective review of 5640 patients in a community teaching hospital with an annual ED census of 31,000, cancer history was identified in 5% of patients. Ten percent of patients with oncology-related visits died during the admission, and 48% died within 1 year of the ED visit.3



Pathophysiology


White blood cells (WBCs), or leukocytes, are the primary cells responsible for the inflammatory and immune response. WBCs include granulocytes (neutrophils, eosinophils, basophils) and mononuclear cells (T and B lymphocytes, monocytes). These cells are all produced from a common stem cell in the bone marrow, and they differentiate through various cytokines including colony-stimulating factors and interleukins. Normal blood leukocyte counts are 4.34 to 10.8 × 109/L, with neutrophils representing 45% to 74% of cells, bands representing 0% to 4%, lymphocytes representing 16% to 45%, monocytes representing 4% to 10%, eosinophils representing 0% to 7%, and basophils representing 0% to 2%.4 WBC disorders are the result of cell overproduction, underproduction, or dysfunction (Box 203.1). The WBC count with differential lacks specificity and sensitivity but is the most frequent laboratory test ordered by emergency physicians.5







White Blood Cell Malignancy


Although WBC disorders have a vast differential diagnosis, the remainder of this chapter focuses on hematologic malignant diseases. Leukemias, lymphomas, and plasma cell disorders are the main general categories of these malignant diseases.


Leukemias are a result of failure of differentiation of hematopoietic precursor cells that leads to unchecked proliferation of blasts, either immature myeloid or lymphoid cells, which impede the normal manufacturing of red blood cells, WBCs, and platelets in the bone marrow. Anemia, bleeding, and infection are a result of decreased normal cell production. Eventually, blasts multiply and migrate throughout other hematopoietic organs including the spleen and lymph nodes. In acute leukemias, WBC counts vary greatly (25% of patients have counts <5000/microliters, 25% have counts >50,000/microliters, and 50% have counts between 5000 and 50,000/microliters), but anemia, thrombocytopenia, and blasts are common. Bone marrow aspiration and biopsy are used to diagnose leukemias definitively.


Lymphomas are a vast group of malignant diseases defined by clonal proliferation of malignant lymphocytes. The World Health Organization lymphoma classification defined 27 types of lymphomas categorized primarily by the primary clonal cells: B cells, T cells, or natural killer cells. Lymphocytosis and varied characteristic cells are present on a peripheral blood smear. Lymph node and bone marrow biopsy also aid in the diagnosis.


Monoclonal proliferation of immunoglobin-secreting plasma cells characterizes plasma cell disorders. These conditions include multiple myeloma, monoclonal gammopathies, Waldenström macroglobulinemia, heavy-chain diseases, cryoglobulinemia, and primary amyloidosis. These diseases are diagnosed by using serum or protein electrophoresis and bone marrow analysis.



Presenting Signs and Symptoms


Nonspecific presentations of liquid malignant diseases are common, but prompt recognition of these signs and symptoms is essential for rapid treatment of immunocompromised patients. Initial presentations of malignancy vary greatly from subtle historical features or physical findings to in extremis shock states typically resulting from complications and grave immunodeficiency. Patients with known malignant disease also have variable presenting complaints based on the type of malignant disease, the burden of disease, and current oncologic therapeutic regimens.



Acute Myelogenous and Lymphoid Leukemias



Acute Myelogenous Leukemia


Patients with leukemia present with signs and symptoms secondary to the invasion of other organs by leukemic cells and decreased production of normal hematopoietic cells. Fever, malaise, and a viral-like syndrome are common presenting symptoms. Diffuse bony tenderness, as a result of expansion of the intramedullary space or periosteal infiltration by leukemic cells, is the initial symptom in 25% of patients.9


Acute myelogenous leukemia (AML) typically affects all three cells lines and results in anemia, thrombocytopenia, and neutropenia. Pallor, dyspnea, and chest pain reflect anemia, whereas petechiae, ecchymosis, and excessive bleeding are a result of thrombocytopenia. One third of patients will have significant infections on diagnosis.10 Splenomegaly occurs in up to 50% of patients, and lymphadenopathy is rare.9


AML has several skin manifestations. Raised, nontender plaques or nodules (leukemia cutis) are manifest in many forms of leukemia, but they are most commonly seen in AML (Fig. 203.2).11 Tender, pseudovesicular, erythematous plaques are a characteristic feature of Sweet syndrome, which may precede the diagnosis of AML by months (Fig. 203.3). Gingival hyperplasia may also be present (Fig. 203.4).




Jun 14, 2016 | Posted by in EMERGENCY MEDICINE | Comments Off on White Blood Cell Disorders

Full access? Get Clinical Tree

Get Clinical Tree app for offline access